U 46619: Selective TP Receptor Agonist for Platelet Aggregation and Vascular Research

Executive Summary: U 46619 (11,9 epoxymethano-prostaglandin H2) is a synthetic agonist targeting prostaglandin H2 (PGH2) and thromboxane A2 (TxA2) receptors (TP receptors), central to platelet function and vascular tone regulation (APExBIO). At nanomolar concentrations (EC50 = 0.035 μM) it induces platelet shape change, while higher concentrations drive aggregation and serotonin release. The compound's selectivity and solubility underpin its widespread use in cardiovascular and renal hemodynamics research (Benchmark Platelet Aggregation Inducer). U 46619 supports robust, reproducible workflows for modeling hypertension and G-protein coupled receptor (GPCR) signaling (Strategic Implementation).

Biological Rationale

Prostaglandins and thromboxanes are lipid mediators central to vascular homeostasis and platelet activation. The thromboxane A2 receptor (TP receptor) is a G-protein coupled receptor (GPCR) that transduces signals regulating platelet aggregation, vasoconstriction, and blood pressure. U 46619 is a stable synthetic analogue of PGH2, structurally optimized to resist rapid metabolic degradation and selectively activate TP receptors. This selectivity allows researchers to dissect TP-mediated pathways, avoiding off-target effects associated with endogenous ligands. The involvement of TP signaling in cardiovascular disease, hypertension, and renal physiology makes U 46619 a critical tool for in vitro and in vivo modeling (Selective Thromboxane Receptor Agonist).

Mechanism of Action of U 46619

U 46619 binds TP (prostaglandin H2/thromboxane A2) receptors with high affinity and selectivity. These receptors couple predominantly to Gq proteins, leading to phospholipase C activation, inositol trisphosphate (IP3) generation, and intracellular Ca²⁺ release. In platelets, this cascade initiates shape change, myosin light chain phosphorylation, and subsequent aggregation. At low nanomolar concentrations, U 46619 triggers cytoskeletal rearrangement (shape change, EC50 = 0.035 μM) and MLCP (EC50 = 0.057 μM). At higher concentrations, it induces serotonin release (EC50 = 0.536 μM), integrin α_IIbβ₃ activation (fibrinogen receptor binding, EC50 = 0.53 μM), and full platelet aggregation (EC50 = 1.31 μM). In vascular smooth muscle, TP agonism leads to vasoconstriction, modulating blood pressure and renal hemodynamics (Dabigatran Review, Table 1).

Evidence & Benchmarks

• U 46619 induces platelet shape change at EC50 = 0.035 μM (in washed human platelets, 37°C, pH 7.2) (APExBIO Product Data).
• Myosin light chain phosphorylation in platelets is triggered at EC50 = 0.057 μM under similar assay conditions (APExBIO).
• EC50 for serotonin release in platelets is 0.536 μM, measured in aggregation buffer (PBS, pH 7.2, 37°C) (Benchmark Platelet Aggregation Inducer).
• EC50 for fibrinogen receptor (integrin α_IIbβ₃) binding is 0.53 μM; full aggregation EC50 is 1.31 μM (same conditions) (Strategic Implementation).
• In vivo, U 46619 increases blood pressure dose-dependently in spontaneously hypertensive rats without significant change in heart rate (Dabigatran Review).
• Renal cortical vasoconstriction and medullary vasodilation observed after TP and endothelin ETA/ETB receptor activation in rat models (Practical Solutions).
• Solubility: ≥100 mg/mL in DMSO, ethanol, DMF; ≥2 mg/mL in PBS at pH 7.2; supplied as 10 mg/mL methyl acetate solution (APExBIO).

Applications, Limits & Misconceptions

U 46619 is established as a reference agonist in:

• Platelet aggregation and activation studies
• Screening of anti-thrombotic agents and NOACs (e.g., dabigatran, as reviewed here)
• Vascular tone and renal hemodynamics research
• Hypertension and cardiovascular disease modeling in animal studies
• Dissecting G-protein coupled receptor signaling specificity

This article extends the quantitative benchmarks detailed in U 46619: Benchmark Platelet Aggregation Inducer by aggregating solubility, EC50, and in vivo cardiovascular efficacy parameters in a single dossier. It further clarifies the translational scope compared to Strategic Implementation, which focused on experimental innovations.

Common Pitfalls or Misconceptions

• U 46619 is not an endogenous ligand and does not recapitulate all PGH2-mediated responses outside TP receptor signaling.
• It is not suitable for direct diagnostic or therapeutic use in humans; for research use only (APExBIO).
• Long-term storage of U 46619 solutions is not recommended; store at -20°C as supplied.
• High concentrations may induce non-TP-mediated effects in some cell systems.
• Not all animal models exhibit identical vascular or platelet responses; species differences must be considered.

Workflow Integration & Parameters

U 46619 (SKU B6890) from APExBIO is supplied as a 10 mg/mL solution in methyl acetate and is compatible with DMSO, ethanol, DMF, and PBS (pH 7.2) for experimental preparation. It is recommended to prepare fresh dilutions before each experiment and store aliquots at -20°C. The compound is widely integrated into platelet aggregation assays, vascular tension studies, and renal function models. For reproducibility, researchers should follow validated EC50 ranges and maintain assay temperature at 37°C. APExBIO’s product documentation provides detailed protocols and handling tips. For troubleshooting and comparative workflow guidance, consult Scenario-Driven Solutions, which this article updates with new EC50 and solubility data.

Conclusion & Outlook

U 46619 remains a gold-standard selective TP receptor agonist for dissecting platelet and vascular biology. Its well-characterized potency, solubility, and receptor selectivity underpin its indispensability in cardiovascular and hypertension research workflows. Continued refinements in assay design and translational modeling will further expand its utility, especially in synergy with emerging anti-thrombotic agents and precision medicine approaches. APExBIO’s commitment to quality and documentation ensures robust, reproducible results for advanced investigation (U 46619 product page).